What are the best treatments for Haemophilia?

The primary treatment for Haemophilia is replacement therapy, which involves infusing the missing clotting factor (Factor VIII for Haemophilia A or Factor IX for Haemophilia B) to prevent or stop bleeding episodes. Modern management often utilizes prophylactic regimens to maintain stable factor levels, supplemented by emerging non-factor therapies and a multidisciplinary care approach tailored to the individual's specific mutation and clinical needs.

What are the first-line treatments for Haemophilia?

For individuals living with Haemophilia, the gold standard of care is factor replacement therapy. This involves intravenous infusion of the specific protein that the patient's body lacks. Treatment can be administered on-demand (at the time of a bleed) or as prophylaxis (scheduled infusions to prevent bleeds before they occur). Prophylactic treatment is widely considered the best practice for severe Haemophilia, as it significantly reduces the incidence of joint damage and long-term disability. In addition to factor concentrates, desmopressin (DDAVP) may be used in mild cases of Haemophilia A to stimulate the release of stored Factor VIII from the body's tissues.

What medications are commonly prescribed?

Physicians select medications based on the severity of the condition and the presence of inhibitors (antibodies that attack the infused factor). Common pharmacological options include:

• Recombinant Factor Concentrates: (e.g., Advate, Eloctate, BeneFIX) These are engineered in a lab and carry no risk of blood-borne viral transmission.


• Plasma-derived Factor Concentrates: These are processed from human plasma and are treated to eliminate viruses.


• Emicizumab (Hemlibra): A non-factor replacement therapy that mimics the function of Factor VIII, often used for patients with Haemophilia A, including those who have developed inhibitors.


• Antifibrinolytic agents: (e.g., tranexamic acid) These medications prevent the breakdown of blood clots and are particularly useful for mucosal bleeding, such as dental procedures.

What non-pharmacological treatments are essential?

Comprehensive care for Haemophilia extends beyond medication. Physical therapy is vital to strengthen muscles surrounding joints that may have been damaged by previous bleeds. Occupational therapy helps patients adapt their daily activities to protect joints and minimize injury risk. In cases where chronic joint damage (arthropathy) has occurred, surgical interventions such as synovectomy or joint replacement may be necessary to restore mobility and reduce pain.

How does treatment effectiveness vary between patients?

Treatment success in Haemophilia is highly individualized and depends on several factors, including the patient's baseline factor level, the presence of inhibitors, and their physical activity level. Because 334 people with Haemophilia have already joined the DiseaseMaps community, we know that patient experiences vary significantly. Some individuals require frequent infusions, while others may benefit from newer, longer-acting products that allow for less frequent dosing. Genetic factors also play a role, as the specific mutation in the F8 or F9 gene can influence how a patient responds to different therapies.

Which specialists should be on the care team?

Managing Haemophilia requires a multidisciplinary approach. A comprehensive care team typically includes a haematologist, a specialized nurse, a physical therapist, a social worker, and a clinical psychologist. Genetic counselors are also essential for families navigating the inheritance patterns of the condition.

Next steps

• Consult a specialized haematologist at a recognized Haemophilia Treatment Centre (HTC).


• Discuss the latest prophylactic treatment options with your medical team to see if they fit your lifestyle.


• Connect with the community at DiseaseMaps.org to share experiences and learn from others living with the condition.


• Ensure your care team includes a physical therapist experienced in bleeding disorders to prevent joint damage.

Medical Disclaimer: This information is for educational purposes only and does not replace professional medical advice; please consult your personal physician to develop a treatment plan tailored to your specific clinical needs.

References

• World Federation of Hemophilia (WFH) Guidelines for the Management of Hemophilia.


• NIH Genetic and Rare Diseases Information Center (GARD).


• Orphanet: The portal for rare diseases and orphan drugs.


• OMIM (Online Mendelian Inheritance in Man) database for F8 and F9 gene mutations.